These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29546696)

  • 1. Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study.
    Vazquez-Mellado J; Peláez-Ballestas I; Burgos-Vargas R; Alvarez-Hernández E; García-Méndez S; Pascual-Ramos V; Rull-Gabayet M
    Clin Rheumatol; 2018 Jul; 37(7):1885-1894. PubMed ID: 29546696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
    Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C
    Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
    Whelton A; MacDonald PA; Chefo S; Gunawardhana L
    Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study.
    Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
    Ann Rheum Dis; 2017 Dec; 76(12):2065-2070. PubMed ID: 28830881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?
    Li-Yu J; Clayburne G; Sieck M; Beutler A; Rull M; Eisner E; Schumacher HR
    J Rheumatol; 2001 Mar; 28(3):577-80. PubMed ID: 11296962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are Target Urate and Remission Possible in Severe Gout? A Five-year Cohort Study.
    Alvarado-de la Barrera C; López-López CO; Álvarez-Hernández E; Peláez-Ballestas I; Gómez-Ruiz C; Burgos-Vargas R; Vázquez-Mellado J
    J Rheumatol; 2020 Jan; 47(1):132-139. PubMed ID: 31043541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study.
    Shen M; Zhang J; Qian K; Li C; Xu W; Gu B; Wang X; Ren Q; Yang L; Yuan H; Su D; Chen X
    Clin Rheumatol; 2018 Nov; 37(11):3107-3113. PubMed ID: 30196323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.
    Khanna P; Khanna D; Storgard C; Baumgartner S; Morlock R
    Postgrad Med; 2016 Jan; 128(1):34-40. PubMed ID: 26578028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
    Becker MA; Fitz-Patrick D; Choi HK; Dalbeth N; Storgard C; Cravets M; Baumgartner S
    Semin Arthritis Rheum; 2015 Oct; 45(2):174-83. PubMed ID: 26190562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
    Stamp LK; Chapman PT; Barclay ML; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
    Ann Rheum Dis; 2017 Sep; 76(9):1522-1528. PubMed ID: 28314755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.
    Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
    Arthritis Res Ther; 2017 Dec; 19(1):283. PubMed ID: 29268756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
    Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
    Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The efficacy and tolerability of allopurinol dose escalation in patients with gout].
    Radak-Perović M; Zlatković-Svenda M
    Srp Arh Celok Lek; 2013; 141(5-6):333-6. PubMed ID: 23858803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
    Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares.
    Choi HJ; Lee CH; Lee JH; Yoon BY; Kim HA; Suh CH; Choi ST; Song JS; Joo HY; Choi SJ; Lee JS; Shin KC; Baek HJ
    Int J Rheum Dis; 2017 Apr; 20(4):497-503. PubMed ID: 25160939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with gout differ from healthy subjects in renal response to changes in serum uric acid.
    Liu S; Perez-Ruiz F; Miner JN
    Joint Bone Spine; 2017 Mar; 84(2):183-188. PubMed ID: 27324603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.